Keywords: Novartis, Ilaris, Acute gouty arthritis, European Commission, Regeneron, Royalties

Novartis gets EU approval for expanded use of Ilaris, acute gouty arthritis

Article | 05 March 2013

Print This

The European Commission (EC) has approved Swiss drug major Novartis’ (NOVN: VX) llaris (canakinumab, ACZ885) in the treatment of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in